EA201490982A1 - Аналоги глюкагона - Google Patents

Аналоги глюкагона

Info

Publication number
EA201490982A1
EA201490982A1 EA201490982A EA201490982A EA201490982A1 EA 201490982 A1 EA201490982 A1 EA 201490982A1 EA 201490982 A EA201490982 A EA 201490982A EA 201490982 A EA201490982 A EA 201490982A EA 201490982 A1 EA201490982 A1 EA 201490982A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
treatment
gluacagona
analogue
glucagon
Prior art date
Application number
EA201490982A
Other languages
English (en)
Inventor
Дитер Вольфганг Хампрехт
Якоб Линд Толборг
Дитте Рибер
Original Assignee
Зилэнд Фарма А/С
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зилэнд Фарма А/С, Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Зилэнд Фарма А/С
Publication of EA201490982A1 publication Critical patent/EA201490982A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

В изобретении предложены пептиды - аналоги глюкагона и их применение для стимулирования уменьшения массы тела или предотвращения увеличения массы тела, а также лечения ожирения или избыточной массы тела и связанных с ними состояний. Соединения также можно применять для улучшения контроля гликемии и/или для лечения диабета. Соединения могут опосредовать свое действие, в частности, благодаря увеличенной селективности в отношении рецептора GLP-1 по сравнению с глюкагоном человека.
EA201490982A 2011-12-23 2012-12-19 Аналоги глюкагона EA201490982A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579888P 2011-12-23 2011-12-23
PCT/EP2012/076137 WO2013092703A2 (en) 2011-12-23 2012-12-19 Glucagon analogues

Publications (1)

Publication Number Publication Date
EA201490982A1 true EA201490982A1 (ru) 2015-01-30

Family

ID=47594620

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490982A EA201490982A1 (ru) 2011-12-23 2012-12-19 Аналоги глюкагона

Country Status (20)

Country Link
US (2) US20130316941A1 (ru)
EP (1) EP2793931A2 (ru)
JP (1) JP2015502380A (ru)
KR (1) KR20140114845A (ru)
CN (1) CN104144696A (ru)
AP (2) AP2014007797A0 (ru)
AU (1) AU2012357739A1 (ru)
BR (1) BR112014015681A2 (ru)
CA (1) CA2858949A1 (ru)
EA (1) EA201490982A1 (ru)
HK (1) HK1200369A1 (ru)
IL (1) IL232800A0 (ru)
IN (1) IN2014CN04401A (ru)
MA (1) MA35864B1 (ru)
MX (1) MX2014007120A (ru)
PE (1) PE20142113A1 (ru)
PH (1) PH12014501336A1 (ru)
SG (1) SG11201403377QA (ru)
TN (1) TN2014000224A1 (ru)
WO (1) WO2013092703A2 (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP2664374A1 (en) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Lysin-glutamic acid dipeptide derivatives
PL2875043T3 (pl) 2012-07-23 2017-06-30 Zealand Pharma A/S Analogi glukagonu
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
UA116553C2 (uk) 2012-12-21 2018-04-10 Санофі Пептидна сполука - агоніст рецептора glp-1 i glp
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
SG11201602965WA (en) 2013-10-17 2016-05-30 Zealand Pharma As Acylated glucagon analogues
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
CA2929107C (en) 2013-11-06 2023-09-26 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
CA2975562C (en) 2015-02-17 2020-04-28 Eli Lilly And Company Nasal powder formulation for treatment of hypoglycemia
AU2016232218B2 (en) 2015-03-18 2020-09-10 Boehringer Ingelheim International Gmbh Amylin analogues
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
WO2016166289A1 (en) * 2015-04-16 2016-10-20 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EP3888667B1 (en) 2016-06-09 2023-10-25 AmideBio LLC Glucagon analog and methods of use thereof
ES2874587T3 (es) 2016-08-05 2021-11-05 Boehringer Ingelheim Int Derivados de oxadiazolopiridina para su uso como inhibidores de la grelina O-aciltransferasa (GOAT)
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
CA3043151A1 (en) * 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN117603337A (zh) * 2017-08-16 2024-02-27 东亚St株式会社 酰化胃泌酸调节素肽类似物
EP3746451B1 (en) 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
CA3087925A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
MX2020008116A (es) 2018-02-02 2020-09-25 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CN111349155B (zh) * 2018-12-24 2022-04-05 浙江和泽医药科技股份有限公司 一种胰高血糖素类似物及其制备方法和用途
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
CA3156452A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh NPY2 RECEPTOR AGONISTS
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法
EP4153600A1 (en) 2020-05-22 2023-03-29 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN113278060B (zh) * 2020-05-29 2022-03-25 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE290014T1 (de) 1996-09-09 2005-03-15 Zealand Pharma As Festphasen-peptidsynthese
EP1950223A3 (en) 1998-03-09 2009-05-13 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2006258841B2 (en) 2005-06-13 2012-05-03 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
EP1991574B1 (en) 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
JP5622390B2 (ja) 2006-07-18 2014-11-12 サノフイ 癌治療用対ｅｐｈａ２アンタゴニスト抗体
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2579502T3 (es) 2008-06-17 2016-08-11 Indiana University Research And Technology Corporation Coagonistas de receptores de glucagón/GLP-1
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
PL2370462T3 (pl) * 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
EA022816B1 (ru) * 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
MX342409B (es) * 2010-01-20 2016-09-28 Zealand Pharma As Tratamiento de enfermedades cardiacas.
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon

Also Published As

Publication number Publication date
TN2014000224A1 (en) 2015-09-30
KR20140114845A (ko) 2014-09-29
US20160347813A1 (en) 2016-12-01
IL232800A0 (en) 2014-07-31
JP2015502380A (ja) 2015-01-22
WO2013092703A2 (en) 2013-06-27
CN104144696A (zh) 2014-11-12
CA2858949A1 (en) 2013-06-27
WO2013092703A3 (en) 2013-11-14
HK1200369A1 (en) 2015-10-09
AP2014007774A0 (en) 2014-07-31
MA35864B1 (fr) 2014-12-01
SG11201403377QA (en) 2014-07-30
MX2014007120A (es) 2015-03-05
AP2014007797A0 (en) 2014-07-31
PH12014501336A1 (en) 2014-09-15
BR112014015681A2 (pt) 2019-09-24
PE20142113A1 (es) 2014-12-03
EP2793931A2 (en) 2014-10-29
AU2012357739A1 (en) 2014-07-03
US20130316941A1 (en) 2013-11-28
IN2014CN04401A (ru) 2015-09-04

Similar Documents

Publication Publication Date Title
EA201490982A1 (ru) Аналоги глюкагона
PH12015500531A1 (en) Glucagon analogues
PH12016500675A1 (en) Acylated glucagon analogues
EA201291234A1 (ru) Аналоги глюкагона
MX2016004907A (es) Analogos del glucagon.
MY188182A (en) Acylated glucagon analogues
MX2011006315A (es) Analogos de glucagon.
EA201190054A1 (ru) Аналоги глюкагона
EA201190049A1 (ru) Аналоги глюкагона
EA201190047A1 (ru) Аналоги глюкагона
EA201291233A1 (ru) Аналоги глюкагона
EA201590715A1 (ru) Производные эксендина-4 как двойные агонисты glp1/глюкагона
EA201590011A1 (ru) Пептидные аналоги эксендина-4
EA201591174A1 (ru) Функционализированные производные эксендина-4
MX2017012864A (es) Analogo acilado del glucagon.
TN2011000667A1 (en) Acylated glucagon analogues
CY1116448T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
ECSP15009978A (es) Análogos de glucagón
CO6382136A2 (es) Análogos de glucagón